From Wikipedia, the free encyclopedia
Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is currently being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants.
[edit] External links
|
Humanized monoclonal antibodies ("-zu-") |
|
| "-tuzu-" (tumor) |
Alemtuzumab, Bevacizumab/ Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab, Tucotuzumab celmoleukin
|
|
| "-lizu-" (immune system) |
Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab
|
|
| "-bazu-" (bacterial) |
|
|
| "-cizu-" (cardiovascular) |
|
|
| "-neuzu-" (nervous system) |
|
|
| "-toxazu-" (toxin as target) |
|
|
| "-vizu-" (viral infections) |
|
|
